Skip to main content

Rythmol Disease Interactions

There are 7 disease interactions with Rythmol (propafenone).

Major

Propafenone (applies to Rythmol) bronchospastic disorder

Major Potential Hazard, Moderate plausibility. Applicable conditions: Asthma, Chronic Obstructive Pulmonary Disease

The use of propafenone is contraindicated in patients with bronchospastic disorders or severe obstructive pulmonary disease. Propafenone has beta-adrenergic blocking properties.

Switch to professional interaction data

Major

Propafenone (applies to Rythmol) cardiac dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Heart Block, Hypotension, Congestive Heart Failure

The use of propafenone is contraindicated in patients with uncontrolled congestive heart failure, cardiogenic shock, bradycardia, or marked hypotension. Propafenone can exacerbate congestive heart failure by beta blockade of sympathetic stimulation necessary for circulatory support. Propafenone also has negative inotropic activity that can depress cardiac output and cardiac index.

Switch to professional interaction data

Major

Propafenone (applies to Rythmol) sinus (applies to Rythmol) AV node dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Heart Block

The use of propafenone is contraindicated in patients with conduction disorders such as second- or third-degree AV block, right bundle-branch block when associated with a left hemiblock(bifascicular block), sick sinus syndrome, or bradycardia-tachycardia syndrome in the absence of a functional artificial pacemaker.

Switch to professional interaction data

Moderate

Antiarrhythmics (applies to Rythmol) electrolyte imbalance

Moderate Potential Hazard, High plausibility. Applicable conditions: Hypokalemia, Hyperkalemia, Magnesium Imbalance

Electrolyte imbalance can alter the therapeutic effectiveness of antiarrhythmic agents. Hypokalemia and hypomagnesemia can reduce the effectiveness of antiarrhythmic agents. In some cases, these disorders can exaggerate the degree of QTc prolongation and increase the potential for torsade de pointes. Hyperkalemia can potentiate the toxic effects of antiarrhythmic agents. Electrolyte imbalance should be corrected prior to initiating antiarrhythmic therapy. Clinical monitoring of cardiac function and electrolyte concentrations is recommended.

Switch to professional interaction data

Moderate

Propafenone (applies to Rythmol) (+) ANA titer

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Lupus Erythematosus

Reversible (+) ANA titers have been reported during administration of propafenone. Therapy with propafenone should be administered cautiously in patients with established systemic lupus erythematosus (SLE). Clinical monitoring, including ANA titers, is recommended. Patients without a previous history of (+) ANA titer or SLE who develop a (+) ANA while receiving propafenone should be evaluated and, if ANA titers persist or worsen, discontinuation of therapy should be considered.

Switch to professional interaction data

Moderate

Propafenone (applies to Rythmol) liver disease

Moderate Potential Hazard, High plausibility.

Propafenone is extensively metabolized by the liver. The bioavailability of propafenone in patients with normal hepatic function is approximately 3% to 40%, but increases to approximately 70% in patients with severe hepatic impairment. Therapy with propafenone should be administered cautiously and the dosage reduced to 20% to 30% of that given patients with normal hepatic function. Clinical monitoring of cardiac function (ECG) and hepatic function is recommended.

Switch to professional interaction data

Moderate

Propafenone (applies to Rythmol) renal dysfunction

Moderate Potential Hazard, Low plausibility.

Propafenone is partially eliminated by the kidney and approximately 50% of its metabolites are excreted in the urine. Therapy with propafenone should be administered cautiously in patients with renal impairment, monitoring for signs of overdosage.

Switch to professional interaction data

Rythmol drug interactions

There are 413 drug interactions with Rythmol (propafenone).

Rythmol alcohol/food interactions

There is 1 alcohol/food interaction with Rythmol (propafenone).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer